Digestion

Research Article

An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors

Miyahara K.a · Noda T.a · Ito Y.a · Hidaka H.a · Fujimoto S.a,b · Takedomi H.b · Akutagawa T.b · Sakata Y.b · Shimamura T.c · Tominaga N.c · Yamaguchi D.d · Fujimoto K.e

Author affiliations

aDepartment of Internal Medicine, Karatsu Red Cross Hospital, Saga, Japan
bDepartment of Internal Medicine and Gastroenterology, Saga Medical School, Saga, Japan
cDepartment of Gastroenterology, Saga Medical Centre Koseikan, Saga, Japan
dDepartment of Gastroenterology, National Hospital Organization Ureshino Medical Center, Saga, Japan
eInternational University of Health and Welfare Graduate School, Fukuoka, Japan

Keywords: Immune checkpoint inhibitorsAnti PD-1 antibodiesGastrointestinal immune-related adverse event

Related Articles for ""
Digestion 2020;101:60–65
https://doi.org/10.1159/000504647

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Research Article

Received: October 26, 2019
Accepted: November 08, 2019
Published online: December 04, 2019
Issue release date: January 2020

Number of Print Pages: 6
Number of Figures: 2
Number of Tables: 2

ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (Online)

For additional information: https://www.karger.com/DIG

Abstract

Introduction/Aims: Immune checkpoint inhibitors (ICIs) sometimes cause immune-related adverse events (irAEs), of which there is little information in the literatures. The objective of this study was to characterize the clinical features of gastrointestinal irAEs (GI irAEs). Materials and Methods: From a total of 250 patients who were administered anti-PD-1 antibodies (nivolumab and pembrolizumab), we retrospectively identified 9 patients with grade 2 or higher GI irAE based on medical records. Patient characteristics, clinical features, imaging and pathological findings, and treatment course were evaluated. Results: Grade 2 or higher GI irAEs were observed in 9 (3.6%) patients. Of the 9 patients who experienced GI irAE, 8 were male, and mean age was 63.2 years. Five patients received nivolumab and 4 received pembrolizumab. The GI irAEs observed were diarrhea in 7 patients and bloody stool in 2 patients. Grade 2 GI irAEs were identified in 3 patients and grade 3 GI irAEs in 6 patients. The average time from ICI administration to the onset of GI irAEs was 22.2 weeks (range 7–56 weeks) for nivolumab and 19.7 weeks (range 11–28 weeks) for pembrolizumab. Endoscopic findings showed ulcerative colitis-like findings in 3 of 7 patients, and pathological examination revealed crypt epithelial cell apoptosis in 6 of 7 patients. Eight of the 9 patients received steroids, and 2 patients received infliximab additionally. All GI irAEs were manageable. Conclusions: Because of the lack of specific clinical, imaging, and pathological findings, information of ICI use was indispensable for diagnosis. Although GI irAEs are controllable by steroid and infliximab, further studies regarding management strategy will be needed.

© 2019 S. Karger AG, Basel



Related Articles:

References

  1. Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017 Oct;28(10):2377–85.
  2. Kim KW, Ramaiya NH, Krajewski KM, Shinagare AB, Howard SA, Jagannathan JP, et al. Ipilimumab-associated colitis: CT findings. AJR Am J Roentgenol. 2013 May;200(5):W468–74.
  3. Kikuchi H, Sakuraba H, Akemoto Y, Murai Y, Fukutoku Y, Asari T, et al. A case of nivolumab-associated colitis, which relapsed after mucosal healing and was then successfully treated with mesalazine. Immunol Med. 2019 Mar;42(1):39–44.
  4. Assarzadegan N, Montgomery E, Anders RA. Immune checkpoint inhibitor colitis: the flip side of the wonder drugs. Virchows Arch. 2018 Jan;472(1):125–33.
  5. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015 Jan;372(4):320–30.
  6. Weber JS. Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist. Am Soc Clin Oncol Educ Book. 2012;32:174–7.
  7. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al.; KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015 Jun;372(26):2521–32.
  8. Tandon P, Bourassa-Blanchette S, Bishay K, Parlow S, Laurie SA, McCurdy JD. The risk of diarrhea and colitis in patients with advanced melanoma undergoing immune checkpoint inhibitor therapy: A systematic review and meta-analysis. J Immunother. 2018 Apr;41(3):101–8.
  9. EMA, European Public Assessment Report. Nivolumab-BMS(EMA/CHMP/392114/ 2015).
  10. EMA, European Public Assessment Report Opdivo (EMA/CHMP/76688/2015.)
  11. EMA, European Public Assessment Report. Keytrude (EMA/CHMP/44458/2015).
  12. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016 Nov;375(19):1845–55.
  13. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug;363(8):711–23.
  14. Marthey L, Mateus C, Mussini C, Nachury M, Nancey S, Grange F, et al. Cancer immunotherapy with Anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohn’s Colitis. 2016 Apr;10(4):395–401.
  15. Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016 Feb;2(2):234–40.
  16. Kähler KC, Eigentler TK, Gesierich A, Heinzerling L, Loquai C, Meier F, et al.; German Dermatologic Cooperative Oncology Group (DeCOG). Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. Cancer Immunol Immunother. 2018 May;67(5):825–34.
  17. Bhatia S, Huber BR, Upton MP, Thompson JA. Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. J Immunother. 2009 Feb-Mar;32(2):203–5.
  18. Gaudy-Marqueste C, Monestier S, Franques J, Cantais E, Richard MA, Grob JJ. A severe case of ipilimumab-induced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J Immunother. 2013 Jan;36(1):77–8.
  19. Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Grünwald V, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev. 2016 Apr;45:7–18.
  20. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015 May;16(5):522–30.
  21. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016 Mar;44:51–60.
  22. Gentile NM, D’Souza A, Fujii LL, Wu TT, Murray JA. Association between ipilimumab and celiac disease. Mayo Clin Proc. 2013 Apr;88(4):414–7.
  23. Nasuno M, Miyakawa M, Tanaka H, Motoya S. Short-and long-term outcomes of infliximab treatment for steroid-refractory ulcerative colitis and related prognostic factors: A single-center retrospective study. Digestion. 2017;95(1):67–71.
  24. Collins M, Michot JM, Danlos FX, Mussini C, Soularue E, Mateus C, et al. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Ann Oncol. 2017 Nov;28(11):2860–5.
  25. Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016 Jun;60:190–209.
  26. Yanai S, Nakamura S, Matsumoto T. Nivolumab-induced colitis treated by infliximab. Clin Gastroenterol Hepatol. 2017 Apr;15(4):e80–1.
  27. Bergqvist V, Hertervig E, Gedeon P, Kopljar M, Griph H, Kinhult S, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother. 2017 May;66(5):581–92.
  28. Kubo K, Kato M, Mabe K. Nivolumab-associated colitis mimicking ulcerative colitis. Clin Gastroenterol Hepatol. 2017 Sep;15(9):A35–6.
  29. Stroud CR, Hegde A, Cherry C, Naqash AR, Sharma N, Addepalli S, et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract. 2019 Apr;25(3):551–7.
  30. Bertha M, Bellaguara E, Kuzel T, Hanauer S. Checkpoint inhibitor–induced colitis: A new type of inflammatory bowel disease? ACG Case Rep J. 2017 Oct;4(1):e112.

Article / Publication Details

First-Page Preview
Abstract of Research Article

Received: October 26, 2019
Accepted: November 08, 2019
Published online: December 04, 2019
Issue release date: January 2020

Number of Print Pages: 6
Number of Figures: 2
Number of Tables: 2

ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (Online)

For additional information: https://www.karger.com/DIG

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2020, Vol.101, No. 1

January 2020

Article

Recommend This
TOP